Prescribing information is available by clicking the links at the bottom of the page

DYSLIPIDEMIA

CARDIOLOGY

What's the Future of Secondary Care Lipid Services?

<h3>What's the Future of Secondary Care Lipid Services?</h3>
Length: 7:35
Dr Jaimini Cegla&nbsp;discusses what the future of secondary care lipid services looks like, covering management of patients with premature cardiovascular disease, residual risk, other dyslipidaemias, specialist treatments and rare dyslipidaemias.

Strengthening the Interface between Primary and Secondary Care | Praluent&reg; (alirocumab)

The Continuing Role of Secondary Care in Lipid Optimisations Post-ACS | Praluent&reg; (alirocumab)

Implementing Artifical Intelligence to Risk Stratify, Manage and Refer Patients | Praluent&reg; (alirocumab)

Get in touch with the Dyslipidaemia Team

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{55f30477-c7e2-49c0-8cfc-16966f28d4c2},repository:{dam},path:{/Portal/UK/Prescribing-links/Praluent-PI-GB-October-2022.pdf}}}" target="_blank">Prescribing Information GB</a> <a href="${link:{uuid:{9e0d6f97-2ebb-4422-92ab-569b89c7dfe0},repository:{dam},path:{/Portal/UK/Prescribing-links/Praluent-PI-NI.pdf}}}" target="_blank">Prescribing Information NI</a></td>
 </tr>
 </tbody>
</table>

<a href="${link:{uuid:{cff3e6a2-9720-40df-834d-e5fed873dcd2},repository:{products},path:{/UK/praluent}}}">More About Praluent® (alirocumab)</a>

<a href="/uk/dyslipidaemia/resources/praluent-patient-support">Patient Support</a>

Praluent® (alirocumab) Prescribing Information (GB)

Praluent® (alirocumab) Prescribing Information (NI)

Diabetes &amp; Exercise Masterclass: supporting your patients with Type 1 diabetes on a MDI and CGM with their exercise goals&nbsp;| Toujeo&reg;&nbsp;(insulin glargine 300 Units/mL) | Lantus&reg;&nbsp;(insulin glargine 100 units/mL)

Cultural humility in diabetes consultation

<a href="/uk/learnings">MORE EDUCATIONAL CONTENT</a>

Get in touch with the Diabetes Team

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{97e86e26-07fe-49e8-b6f3-31758c4a1495},repository:{dam},path:{/Portal/UK/Prescribing-links/Lantus_GB.pdf}}}" target="_blank">Prescribing Information GB</a> <a href="${link:{uuid:{c13c2982-4e19-403a-91b1-4bad9b7bcc86},repository:{dam},path:{/Portal/UK/Prescribing-links/Lantus_NI.pdf}}}" target="_blank">Prescribing Information NI</a></td>
 </tr>
 </tbody>
</table>

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{2a02177b-5764-4cb8-98b6-34b9445e0571},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo-gb.pdf}}}">Prescribing Information GB</a> <a href="${link:{uuid:{1c698db8-7640-4fcd-b5c0-e84b58eb504a},repository:{dam},path:{/Portal/UK/Prescribing-links/toujeo-pi-ni.pdf}}}" target="_blank">Prescribing Information NI</a></td>
 </tr>
 </tbody>
</table>

TYPE-1-DIABETES

TYPE-2-DIABETES

DIABETES

Diabetes UK 2023:
Multifactorial approach to diabetes management

<a href="${link:{uuid:{f34a87f8-75d0-4459-a2d8-c10d6469758f},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo-combined.pdf}}}" target="_blank">Prescribing Information Toujeo (insulin glargine 300 units/mL)</a> <a href="${link:{uuid:{8f132346-a5c2-470d-8368-64ab56220e08},repository:{dam},path:{/Portal/UK/Prescribing-links/Lantus_GB_NI_PI.pdf}}}" target="_blank">Prescribing Information Lantus (insulin glargine 100 units/mL)</a>

<h2>Time in Range - An alternative or useful addition to HbA1c in Type 1 Diabetes?</h2>

Dr Amar Puttanna, Dr Emma Wilmot and Su Down 
 (Promotional content from Sanofi) 
 18 mins
In this episode, Dr Amar Puttanna, Dr Emma Wilmot and Su Down compare and contrast use of HbA1c with Time in Range as a measure of glycaemic control, and discuss the potential implications of their use in clinical practise in the future.
The InRange study is the first randomised controlled trial to use Time in Range as a primary endpoint to compare the second-generation basal insulin basal insulin analogues Toujeo (insulin glargine 300 U/mL) and insulin degludec 100 U/mL in people with type 1 diabetes.1&nbsp;
MAT-XU-2300809 (v1.0) | February 2023

EPISODE 1 Time in Range - An alternative or useful addition to HbA1c in Type 1 Diabetes?

Reference
<ol>
 <li>Battelino T et al. Diabetes Ther 2020;11:1017-1027</li>
</ol>

<h2>Socioeconomic barriers and disparities to diabetes technology</h2>

Professor Partha Kar 
 (Promotional content from Sanofi) 
 13 mins
In this episode, Professor Partha Kar looks into the ongoing inequalities in uptake and awareness of continuous glucose monitoring (CGM). Despite recent advances in access to CGM through the NHS for people with Type 1 diabetes, there exist both racial and socioeconomic disparities in use of this technology.1
Professor Kar considers aspects of CGM access for people with Type 1 and Type 2 diabetes, and examines the causes of, and potential solutions to, inequalities in the use of CGM.&nbsp;
MAT-XU-2300810&nbsp;(v1.0) | February 2023

EPISODE 2 Socioeconomic barriers and disparities to diabetes technology

Reference
<ol>
 <li>Catherine JP, et al. EClinicalMedicine. 2012;42:101186</li>
</ol>

<h2>The role of second-generation basal insulins and CGM in optimising glycaemic control: The InRange study</h2>

Professor Pratik Choudhary 
 (Promotional content from Sanofi) 
 12 mins
In this episode, Professor Pratik Choudhary discusses the findings from the first randomised, Phase 4 study to use TIR as the primary endpoint to compare second-generation basal insulin analogues, Toujeo and insulin degludec 100 U/mL, in people with T1D.1
MAT-XU-2300811&nbsp;(v1.0) | February 2023

EPISODE 3 The role of second-generation basal insulins and CGM in optimising glycaemic control

References
<ol>
 <li>Battelino T et al. Diabetes Ther 2020;11:1017-1027</li>
</ol>

<h2>The challenge of managing the older person with diabetes</h2>

Dr Amar Puttanna, Kathy Davies and Sarah Gregory 
 (Promotional content from Sanofi) 
 19 mins
In this episode, Dr Amar Puttanna, Kathy Davies and Sarah Gregory will discuss some of the challenges when caring for the older person with diabtees and Sanofi's role in supporting the care of older people with diabetes, particularly those in care homes.
MAT-XU-2300812&nbsp;(v1.0) | February 2023

EPISODE 4 The challenge of managing the older person with diabetes

Promotional podcasts on a variety of different topics and meetings that have been organised and funded by Sanofi

Prescribing Information Toujeo (insulin glargine 300 units/mL)

Prescribing Information Lantus (insulin glargine 100 units/mL)

Diabetes Podcast Series | Toujeo® (insulin glargine 300 Units/mL) | Lantus® (insulin glargine 100 units/mL) 

Prescribing information is available by clicking the links at the bottom of the page

Diabetes &amp; Exercise Masterclass: supporting your patients with Type 1 diabetes on a MDI and CGM with their exercise goals | Toujeo&reg;&nbsp;(insulin glargine 300 Units/mL) | Lantus&reg; (insulin glargine 100 units/mL)&nbsp;

Multifactorial approach to diabetes management

<a href="/uk/type-2-diabetes/education">MORE EDUCATIONAL CONTENT</a>

<table border="1" cellpadding="1" cellspacing="1" style="width:500px;">
 <tbody>
 <tr>
 <td>
 <a href="${link:{uuid:{2a02177b-5764-4cb8-98b6-34b9445e0571},repository:{dam},path:{/Portal/UK/Prescribing-links/Toujeo-gb.pdf}}}" target="_blank">Prescribing Information GB</a> <a href="${link:{uuid:{1c698db8-7640-4fcd-b5c0-e84b58eb504a},repository:{dam},path:{/Portal/UK/Prescribing-links/toujeo-pi-ni.pdf}}}" target="_blank">Prescribing Information NI</a></td>
 </tr>
 </tbody>
</table>

Diabetes UK 2023: Cultural humility in diabetes consultation

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are now leaving the Sanofi campus UK website

You are about to leave Campus.sanofi/uk.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch.

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your QFITLIA Representative or receive updates about QFITLIA. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v6.0) - Date of Preparation: April 2024

Welcome to Sanofi Campus UK

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Education

What's the Future of Secondary Care Lipid Services?

Diabetes UK 2023: Multifactorial approach to diabetes management

Diabetes Podcast Series | Toujeo® (insulin glargine 300 Units/mL) | Lantus® (insulin glargine 100 units/mL)

Diabetes UK 2023: Cultural humility in diabetes consultation